Role of Bone Marrow Mesenchymal Stem Cells in Resistance of Chronic Myeloid Leukemia to Tyrosine Kinase Inhibitors -Review.
10.7534/j.issn.1009-2137.2016.06.053
- Author:
Xiao-Yan ZHANG
1
;
Qian WAN
2
;
Li-Jun FANG
2
;
Jian LI
3
Author Information
1. The Key Laboratory of Hematology of Jiangxi Province, The Second Affiliated Hospital of Nanchang University; Graduate School of Medicine; Basic Medical School, Nanchang University, Nanchang 330006, Jiangxi Province, China.
2. The Key Laboratory of Hematology of Jiangxi Province, The Second Affiliated Hospital of Nanchang University
3. The Key Laboratory of Hematology of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China. E-mail: jeniferjian@gmail.com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2016;24(6):1901-1904
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia (CML) is a disease originated from malignant hematopoietic stem cell disorder. In CML, mesenchymal stem cells(MSC) have been changed in the bone marrow microenvironment, which can protect the leukemia cells from apoptosis induced by tyrosine kinase inhibitors (TKI) and lead to the resistance to TKI by the secretion of soluble factors, involvement in cell-cell adhesion, and so on. This review mainly focuses on the changes of the bone marrow mesenchymal stem cells in CML, as well as the role and mechanism of MSC in the CML resistance of TKI. The concrete probrems dicussing in this review are role of MSC in bone marrow microenviroment, characteristics of MSC in CML, the related mechanisms of MSC in drug resistance and so on.
